Cargando…
Genetic alterations in MED12 promote castration-resistant prostate cancer through modulation of GLI3 signaling
Prostate cancer is a disease that depends on androgenic stimulation and is thus commonly treated with androgen deprivation therapy (ADT). ADT is highly successful initially; however, patients inevitably relapse at which point the cancer grows independently of androgens and is termed castration-resis...
Autores principales: | Duong, Thu Minh, Araujo Rincon, Mariana, Myneni, Nishanth, Burleson, Marieke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shiraz University
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382901/ https://www.ncbi.nlm.nih.gov/pubmed/37520466 http://dx.doi.org/10.22099/mbrc.2023.47346.1828 |
Ejemplares similares
-
Gli2 mediates the development of castration-resistant prostate cancer
por: Xia, Lu, et al.
Publicado: (2020) -
BCAR4 activates GLI2 signaling in prostate cancer to contribute to castration resistance
por: Cai, Zhiping, et al.
Publicado: (2018) -
The role of mediator subunit 12 in tumorigenesis and cancer therapeutics
por: Gonzalez, Cristian G., et al.
Publicado: (2022) -
Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin
por: Mak, Blossom, et al.
Publicado: (2022) -
Castration for Prostatic Hypertrophy
Publicado: (1899)